Vor Biopharma (VOR) Cash & Equivalents (2020 - 2026)
Vor Biopharma (VOR) posted quarterly Cash & Equivalents of $169.9 million for Q1 2026, up 239.43% year-over-year from $50.0 million in Q1 2025, and down 57.16% quarter-over-quarter from $396.5 million in Q4 2025.
Vor Biopharma (VOR) Cash & Equivalents (2020 - 2026) Analysis & Trends
Vor Biopharma (VOR) has reported Cash & Equivalents for 7 consecutive years, with $169.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash & Equivalents rose 239.43% year-over-year to $169.9 million; the TTM figure through Mar 2026 stood at $169.9 million (up 239.43% YoY), while the FY2025 annual figure was $396.5 million, up 383.82% from the prior year.
- Cash & Equivalents eased to $169.9 million in Q1 2026 per VOR's latest filing, from $396.5 million in the prior quarter.
- Across five years, Cash & Equivalents topped out at $396.5 million in Q4 2025 and bottomed at $31.4 million in Q4 2023.
- Historically, Cash & Equivalents has averaged $96.8 million across 5 years, with a median of $60.8 million in 2022.
- Annual changes were most pronounced in 2022 — Cash & Equivalents tumbled 65.71% — and 2025, when it jumped 383.82%.
- Vor Biopharma's Cash & Equivalents stood at $57.7 million in 2022, then slumped by 45.66% to $31.4 million in 2023, then soared by 161.32% to $81.9 million in 2024, then surged by 383.82% to $396.5 million in 2025, then sank by 57.16% to $169.9 million in 2026.
- Business Quant data shows VOR's Cash & Equivalents at $169.9 million in Q1 2026, $396.5 million in Q4 2025, and $160.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 6.14 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 2.46 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 3.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 815.44 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.37 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 811.99 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.71 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 544.80 Mn |
| 10 | Vor Biopharma | 1.36 Bn | 1.36 Bn | - | 107.86 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 107.86 Mn |
| Mar 31, 2026 | 169.87 Mn |
| Dec 31, 2025 | 396.49 Mn |
| Sep 30, 2025 | 160.46 Mn |
| Jun 30, 2025 | 190.57 Mn |
| Mar 31, 2025 | 50.05 Mn |
| Dec 31, 2024 | 81.95 Mn |
| Sep 30, 2024 | 52.80 Mn |
| Jun 30, 2024 | 76.08 Mn |
| Mar 31, 2024 | 44.96 Mn |
| Dec 31, 2023 | 31.36 Mn |
| Sep 30, 2023 | 45.03 Mn |
| Jun 30, 2023 | 32.21 Mn |
| Mar 31, 2023 | 42.46 Mn |
| Dec 31, 2022 | 57.71 Mn |
| Sep 30, 2022 | 60.83 Mn |
| Jun 30, 2022 | 62.95 Mn |
| Mar 31, 2022 | 90.04 Mn |
| Dec 31, 2021 | 119.80 Mn |
| Sep 30, 2021 | 143.03 Mn |